The DOI matches its Crossref record; 296 of the 296 references it cites were found in a registry or an index.
GSK-3 as potential target for therapeutic intervention in cancer
Open accessAbstract
// James A. McCubrey 1 , Linda S. Steelman 1 , Fred E. Bertrand 2 , Nicole M. Davis 1 , Melissa Sokolosky 1 , Steve L. Abrams 1 , Giuseppe Montalto 3 , Antonino B. D’Assoro 4 , Massimo Libra 5 , Ferdinando Nicoletti 5 , Roberta Maestro 6 , Jorg Basecke 7,8 , Dariusz Rakus 9 , Agnieszka Gizak 9 Zoya Demidenko 10 , Lucio Cocco 11 , Alberto M. Martelli 11 and Melchiorre Cervello 12 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC, USA 2 Department of Oncology, Brody School of Medicine at East Carolina University Greenville, NC, USA 3 Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy 4 Department of Medical Oncology, Mayo Clinic Cancer Center, Rochester, MN, USA 5 Department of Bio-Medical Sciences, University of Catania, Catania, Italy 6 Experimental Oncology 1, CRO IRCCS, National Cancer Institute, Aviano, Pordenone, Italy. 7 Department of Medicine, University of Göttingen, Göttingen, Germany 8 Sanct-Josef-Hospital Cloppenburg, Department of Hematology and Oncology, Cloppenburg, Germany 9 Department of Animal Molecular Physiology, Institute of Experimental Biology, Wroclaw University, Wroclaw, Poland 10 Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA 11 Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy 12 Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy”, Palermo, Italy Correspondence: James A. McCubrey, email: // Keywords : GSK-3, cancer stem cells, Wnt/beta-catenin, PI3K, Akt, mTOR, Hedgehog, Notch, Targeted Therapy, Therapy Resistance, Mutations, Rapamycin Received : April 24, 2014 Accepted : May 28, 2014 Published : May 28, 2014 Abstract The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated in many human pathologies including: bipolar depression, Alzheimer’s disease, Parkinson’s disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been developed, their use remains controversial because of the ambiguous role of GSK-3 in cancer development. In this review, we will focus on the diverse roles that GSK-3 plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has also been implicated in the generation of cancer stem cells in various cell types. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, Notch and others.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–296 of 296
The hematopoietic effects of lithium.
Boggs, D. R., & Joyce, R. A. (1983) · PubMed · Cited by 83
Dysregulation of glycogen synthase kinase-3β signaling in hepatocellular carcinoma cells
Desbois‐Mouthon, C., Eggelpoël, M.-J. B.-V., Beurel, E., Boissan, M., Delélo, R., Cadoret, A., & Capeau, J. (2002) · Hepatology · doi:10.1053/jhep.2002.37192 · Cited by 82
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response
Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Martin-Castillo, B., & Menendez, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15423 · Cited by 81
t-Darpp Promotes Cancer Cell Survival by Up-regulation of Bcl2 through Akt-Dependent Mechanism
Belkhiri, A., Dar, A. A., Zaika, A. I., Kelley, M., & El-Rifai, W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1580 · Cited by 80
Kitano, A., Shimasaki, T., Chikano, Y., Nakada, M., Hirose, M., Higashi, T., Ishigaki, Y., Endo, Y., Takino, T., Sato, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055289 · Cited by 79
Iwai, S., Katagiri, W., Kong, C., AMEKAWA, S., Nakazawa, M., & Yura, Y. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0027-y · Cited by 79
Henriksen, E. J. (2010) · Current Diabetes Reviews · doi:10.2174/157339910793360888 · Cited by 78
Thamilselvan, V., Menon, M., & Thamilselvan, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25949 · Cited by 77
Jin, Y. H., Kim, H., Ki, H., Yang, I., Yang, N.-R., Lee, K. Y., Kim, N., Park, H.-S., & Kim, K. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.10.002 · Cited by 77
Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress
Gall, J. M., Wong, V., Pimental, D. R., Havasi, A., Wang, Z., Pastorino, J. G., Bonegio, R. G. B., Schwartz, J. H., & Borkan, S. C. (2011) · Kidney International · doi:10.1038/ki.2010.532 · Cited by 75
GSK-3β activity and hyperdopamine-dependent behaviors
Li, Y., & Gao, W. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.08.001 · Cited by 74
Targeting GSK-3 family members in the heart: A very sharp double-edged sword
Cheng, H., Woodgett, J. R., Maamari, M., & Force, T. L. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.11.020 · Cited by 71
Pyko, I. V., Nakada, M., Sabit, H., Teng, L., Furuyama, N., Hayashi, Y., Kawakami, K., Minamoto, T., Fedulau, A., & Hamada, J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt182 · Cited by 71
Velpula, K. K., Dasari, V. R., Tsung, A. J., Dinh, D. H., & Rao, J. S. (2011) · Oncotarget · doi:10.18632/oncotarget.367 · Cited by 70
DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein
An, J., Yang, D.-Y., Xu, Q.-Z., Zhang, S.-M., Huo, Y., Shang, Z., Wang, Y., Wu, D.-C., & Zhou, P. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-32 · Cited by 69
Marchand, B., Tremblay, I., Cagnol, S., & Boucher, M. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr309 · Cited by 68
Bressanin, D., Evangelisti, C., Ricci, F., Tabellini, G., Chiarini, F., Tazzari, P. L., Melchionda, F., Buontempo, F., Pagliaro, P., Pession, A., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.579 · Cited by 68
Self-citationGSK-3 inhibition by an orally active small molecule increases bone mass in rats
Marsell, R., Sisask, G., Nilsson, Y., Sundgren‐Andersson, A. K., Andersson, U., Larsson, S., Nilsson, O., Ljunggren, Ö., & Jonsson, K. B. (2011) · Bone · doi:10.1016/j.bone.2011.11.007 · Cited by 67
Amar, S., Belmaker, R. H., & Agam, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797052484 · Cited by 66
Receptor-Dependent and Tyrosine Phosphatase-Mediated Inhibition of GSK3 Regulates Cell Fate Choice
Kim, L., Harwood, A. J., & Kimmel, A. R. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00269-1 · Cited by 66
Leis, H., Segrelles, C., Ruiz, S., Santos, M., & Paramio, J. M. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10087 · Cited by 64
Liu, H., Xu, L., He, H., Zhu, Y., Liu, J., Wang, S., Chen, L., Wu, Q., Xu, J., & Gu, J. (2012) · Cancer Science · doi:10.1111/cas.12017 · Cited by 63
Bone, H. K., Damiano, T., Bartlett, S. T., Perry, A., Letchford, J., Sanchez-Ripoll, Y., Nelson, A. S., & Welham, M. J. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.11.003 · Cited by 62
Zhou, W., Wang, L., Gou, S., Wang, T., Zhang, M., Liu, T., & Wang, C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.10.033 · Cited by 62
Pharmacologic Induction of CD8 + T Cell Memory: Better Living Through Chemistry
Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000302 · Cited by 61
Glycogen Synthase Kinase-3β Mutagenesis Identifies a Common Binding Domain for GBP and Axin
Ferkey, D. M., & Kimelman, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112363200 · Cited by 61
Phosphorylation and Regulation of -Catenin by Casein Kinase I
Sakanaka, C. (2002) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a003276 · Cited by 61
Thermogenic and metabolic antiobesity drugs: rationale and opportunities
Clapham, J. C., & Arch, J. R. S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00608.x · Cited by 60
Chiarini, F., Lonetti, A., Teti, G., Orsini, E., Bressanin, D., Cappellini, A., Ricci, F., Tazzari, P. L., Ognibene, A., Falconi, M., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.762 · Cited by 58
Self-citationKang, L., Lee, H. B., Bae, H., & Lee, S.-G. (2010) · Phytotherapy Research · doi:10.1002/ptr.3147 · Cited by 56
GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines
Panka, D. J., Cho, D. C., Atkins, M. B., & Mier, J. W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705343200 · Cited by 56
GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb
Zhou, F., Zhang, L., van Laar, T., van Dam, H., & ten Dijke, P. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-06-0483 · Cited by 55
GSK3β positively regulates Hedgehog signaling through Sufu in mammalian cells
Takenaka, K., Kise, Y., & Miki, H. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.058 · Cited by 55
Elevated PI3K signaling drives multiple Breast Cancer subtypes
Adams, J. R., Schachter, N. F., Liu, J. C., Zacksenhaus, E., & Egan, S. E. (2011) · Oncotarget · doi:10.18632/oncotarget.285 · Cited by 53
The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells
Genovese, G., Ghosh, P., Li, H., Rettino, A., Sioletic, S., Cittadini, A. R. M., & Sgambato, A. (2012) · Cell Cycle · doi:10.4161/cc.20765 · Cited by 53
Nifoussi, S. K., Vrana, J. A., Domina, A. M., Biasio, A. D., Gui, J., Gregory, M. A., Hann, S., & Craig, R. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047060 · Cited by 53
Targeting translation in acute myeloid leukemia: A new paradigm for therapy?
Tamburini, J., Green, A. S., Chapuis, N., Bardet, V., Lacombe, C., Mayeux, P., & Bouscary, D. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10091 · Cited by 53
Sokolosky, M. L., Chappell, W. H., Stadelman, K. M., Abrams, S. L., Davis, N. M., Steelman, L. S., & McCubrey, J. A. (2014) · Cell Cycle · doi:10.4161/cc.27728 · Cited by 52
Self-citationKoo, J., Yue, P., Gal, A. A., Khuri, F. R., & Sun, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2946 · Cited by 52
Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Klamer, G., Song, E. Y., Ko, K.-H., O'Brien, T. A., & Dolnikov, A. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710792065090 · Cited by 52
Col, J. D., & Dolcetti, R. (2008) · Cell Cycle · doi:10.4161/cc.7.18.6733 · Cited by 51
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett, J. T., Chakrabarty, A., & Arteaga, C. L. (2011) · Oncotarget · doi:10.18632/oncotarget.409 · Cited by 51
Bauer, K., Dowejko, A., Bosserhoff, A., Reichert, T. E., & Bauer, R. J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp175 · Cited by 49
Increased number of peripheral blood CD34 + cells in lithium‐treated patients
Ballin, A., Lehman, D., Sirota, P., Litvinjuk, U., & Meytes, D. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00537.x · Cited by 48
de Castro, J., Gamallo, C., Palacios, J., Moreno‐Bueno, G., Rodríguez, N., Feliú, J., & González-Barón, M. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000266 · Cited by 47
Zeng, F.-Y., Dong, H., Cui, J., Liu, L., & Chen, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.017 · Cited by 47
Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells
Beurel, E., Eggelpoël, M.-J. B.-V., Kornprobst, M., Moritz, S., Delelo, R., Paye, F., Housset, C., & Desbois‐Mouthon, C. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.026 · Cited by 46
Kawazoe, H., Bilim, V. N., Ugolkov, A. V., Yuuki, K., Naito, S., Nagaoka, A., Kato, T., & Tomita, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.147 · Cited by 46
Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.315 · Cited by 46
Self-citationRoles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence
Kim, Y., Seo, Y., Park, C., Yoon, S., & Yoon, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05617.x · Cited by 44
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
Piazza, F., Manni, S., Tubi, L. Q., Montini, B., Pavan, L., Colpo, A., Gnoato, M., Cabrelle, A., Adami, F., Zambello, R., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-526 · Cited by 43
Alao, J. P., Stavropoulou, A. V., Lam, E. W. ‐., & Coombes, R. C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-40 · Cited by 43
Zamek‐Gliszczynski, M. J., Abraham, T. L., Alberts, J. J., Kulanthaivel, P., Jackson, K. A., Chow, K. H., McCann, D., Hu, H., Anderson, S., Furr, N. A., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048488 · Cited by 42
Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway
G-Amlak, M., Shahab Uddin, M. S., Mahmud, D. L., Damacela, I., Lavelle, D., Ahmed, M., van Besien, K., & Wickrema, A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02278-7 · Cited by 41
Urbanska, K., Trojanek, J., Valle, L. D., Eldeen, M. B., Hofmann, F., Garcı́a-Echeverrı́a, C., Khalili, K., & Reiss, K. (2006) · Oncogene · doi:10.1038/sj.onc.1210018 · Cited by 40
Mashhedi, H., Blouin, M., Zakikhani, M., David, S., Zhao, Y., Bazile, M., Birman, E., Algire, C., Aliaga, A., Bedell, B. J., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.16.16219 · Cited by 40
Down‐regulation of Notch‐dependent transcription by Akt in vitro
Song, J., Park, S., Kim, M., & Shin, I. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.04.024 · Cited by 40
Martelli, A. M., Chiarini, F., Evangelisti, C., Ognibene, A., Bressanin, D., Billi, A. M., Manzoli, L., Cappellini, A., & McCubrey, J. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.694869 · Cited by 40
Self-citationA beta version of life: p110β takes center stage
Dbouk, H. A., & Backer, J. (2010) · Oncotarget · doi:10.18632/oncotarget.207 · Cited by 40
PI3Kα Inhibitors That Inhibit Metastasis
Schmidt‐Kittler, O., Zhu, J., Yang, J., Liu, G., Hendricks, W. P. D., Christoph Lengauer, C., Gabelli, S. B., Kinzler, K. W., Vogelstein, B., Huso, D. L., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.166 · Cited by 40
Hsing, C., Chen, Y., Chen, C., Huang, W., Lin, M.-C., Tseng, P., Wang, C., Tsai, C., Choi, P.-C., & Lin, C. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31824af68a · Cited by 39
Fu, Y., Hu, D., Qiu, J. G., Xie, X., Ye, F., & Lü, W. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820d7366 · Cited by 39
Novel targeted therapies for mantle cell lymphoma
Alinari, L., Christian, B. A., & Baiocchi, R. A. (2012) · Oncotarget · doi:10.18632/oncotarget.426 · Cited by 38
Mirlashari, M. R., Randen, I., & Kjeldsen‐Kragh, J. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.11.013 · Cited by 38
Regulating the response to targeted MEK inhibition in melanoma
Conrad, W. H., Swift, R. D., Biechele, T. L., Kulikauskas, R. M., Moon, R. T., & Chien, A. J. (2012) · Cell Cycle · doi:10.4161/cc.21645 · Cited by 37
GSK-3 Promotes Cell Survival, Growth, and PAX3 Levels in Human Melanoma Cells
Kubic, J. D., Mascarenhas, J. B., Iizuka, T., Wolfgeher, D., & Lang, D. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0387 · Cited by 37
Han, X., Ju, J.-H., & Shin, I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.111 · Cited by 36
Welham, M. J., Kingham, E., Sanchez-Ripoll, Y., Kumpfmueller, B., Storm, M. P., & Bone, H. K. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390674 · Cited by 36
Ban, J. O., Oh, J. H., Son, S. M., Won, D., Song, H. S., Han, S., Moon, D. C., Kang, K. W., Song, M. J., & Hong, J. T. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.4.15961 · Cited by 36
Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli
Cheng, Y., Huang, W., Chen, C., Tsai, C., Wang, C., Chiu, W. C., Chen, Y., Lin, Y.-S., Chang, C., & Lin, C. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.099 · Cited by 35
Gizak, A., Piróg, M., & Rakus, D. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.11.032 · Cited by 34
Self-citationWnt and Kras signaling-dark siblings in lung cancer
Pacheco-Pinedo, E. C., & Morrisey, E. E. (2011) · Oncotarget · doi:10.18632/oncotarget.305 · Cited by 33
Reconciling the different roles of Gsk3β in “naïve” and “primed” pluripotent stem cells
Singh, A. M., Bechard, M. E., Smith, K. N., & Dalton, S. (2012) · Cell Cycle · doi:10.4161/cc.21110 · Cited by 33
Jaitner, S., Reiche, J. A., Schäffauer, A. J., Hiendlmeyer, E., Herbst, H., Brabletz, T., Kirchner, T., & Jung, A. (2012) · Cell Cycle · doi:10.4161/cc.21790 · Cited by 32
Tullai, J. W., Graham, J. R., & Cooper, G. M. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17321 · Cited by 30
Chou, C., Chou, A., Lin, C.-C., Chen, W.-J., Wei, C., Yang, M., Hsu, C., Lung, F., Loh, J., Howng, S., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19051 · Cited by 29
Palomo, V., Pérez, D. I., Gil, C., & Martı́nez, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391697 · Cited by 28
QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
García, I., Fall, Y., & Gómez, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210792389225 · Cited by 28
Inhibition of Glycogen Synthase Kinase-3
Ougolkov, A. V., & Billadeau, D. D. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-249-6_5 · Cited by 28
Chappell, W. H., Abrams, S. L., Franklin, R. A., LaHair, M. M., Montalto, G., Cervello, M., Martelli, A. M., Nicoletti, F., Candido, S., Libra, M., et al. (2012) · Cell Cycle · doi:10.4161/cc.22786 · Cited by 27
Self-citationRole of STRAP in regulating GSK3β function and Notch3 stabilization
Kashikar, N., Zhang, W., Massion, P. P., Gonzalez, A. L., & Datta, P. K. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15630 · Cited by 27
Fung, T. K., Gandillet, A., & So, C. W. E. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283545615 · Cited by 26
Pml represses tumour progression through inhibition of mTOR
Bernardi, R., Papa, A., Egia, A., Coltella, N., Teruya‐Feldstein, J., Signoretti, S., & Pandolfi, P. P. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100130 · Cited by 26
Sequential effects of lithium on haematopoiesis
Joyce, R. A. (1984) · British Journal of Haematology · doi:10.1111/j.1365-2141.1984.tb03958.x · Cited by 24
Pająk, B., Songin, M., Strosznajder, J. B., & Gajkowska, B. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.05.008 · Cited by 23
Mechanism of Activation of AMPK and Upregulation of OGG1 by Rapamycin in Cancer Cells
Habib, S. L. (2011) · Oncotarget · doi:10.18632/oncotarget.381 · Cited by 18
Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia
Hoellenriegel, J., & Burger, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.341 · Cited by 18
Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells
Sander, S., & Rajewsky, K. (2012) · Oncotarget · doi:10.18632/oncotarget.726 · Cited by 18
Zhang, N., Jiang, Y., Zou, J., Yu, Q., & Zhao, W. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22279 · Cited by 17
Involvement of Glycogen Synthase Kinase-3β in Arsenic Trioxide–Induced p21 Expression
Huang, H., Liu, Z., & Cheng, Y.-L. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr023 · Cited by 17
Songin, M., Strosznajder, J. B., Fitał, M., Kuter, K. Z., Kolasiewicz, W., Nowak, P. G., & Ossowska, K. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9153-7 · Cited by 16
Exploring Pluripotency with Chemical Genetics
Doble, B. W., & Woodgett, J. R. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.01.005 · Cited by 15
The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division
McQueen, J., van Dyk, D., Young, B. P., Loewen, C., & Measday, V. (2012) · Cell Cycle · doi:10.4161/cc.21731 · Cited by 12
Interplay between glycogen synthase kinase‐3β and tau in the cerebellum of Hsp27 transgenic mouse
Wang, S., Toth, M. E., Bereczki, E., Sántha, M., Guan, Z., Winblad, B. G., & Pei, J.-J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22660 · Cited by 11
Shin, S., Wolgamott, L., & Yoon, S.-O. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19784 · Cited by 10
van der Velden, Y. U., & Haramis, A.-P. G. (2011) · Aging · doi:10.18632/aging.100319 · Cited by 10
Cited by
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
Genetics, diagnosis and management of colorectal cancer (Review)
DE ROSA, M., PACE, U., REGA, D., COSTABILE, V., DURATURO, F., IZZO, P., & DELRIO, P. (2015) · Oncology Reports · doi:10.3892/or.2015.4108 · Cited by 317
Acetyl-CoA metabolism in cancer
Guertin, D. A., & Wellen, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00543-5 · Cited by 303
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284
Self-citation
Metadata
- Authors
- McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., Maestro, R., Basecke, J., Rakus, D., Gizak, A., Demidenko, Z., Cocco, L., Martelli, A. M., & Cervello, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-05-28
- Volume
- 5
- Issue
- 10
- Pages
- 2881-2911
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1716978847
- Cited by
- 508
- References
- 296
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.